Photo of Charles D. Lopez, M.D., Ph.D.

Charles D. Lopez M.D., Ph.D.

  • (503) 494-6594
    • Associate Professor of Medicine School of Medicine
    • Cell and Developmental Biology Graduate Program School of Medicine
    • Cancer Biology Graduate Program School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine

My major research interest is investigating the basic cellular and molecular mechanisms of how tumors form and respond to treatment. By studying how these things work, I hope to find specific molecules that are targets for new cancer treatments. I see patients with gastrointestinal (digestive system) cancers and participate in clinical trials for a variety of gastrointestinal cancers.


  • Ph.D., University of California San Francisco California 1990
  • M.D., University of California San Francisco, 0 1991
  • Residency:

    • University of California Medical Center, San Francisco, 1994
  • Fellowship:

    • Medical oncology, Stanford University Medical Center, 1998
  • Certifications:

    • American Board of Internal Medicine, Medical Oncology

Memberships and associations

  • American Society of Clinical Oncology (ASCO)


  • "Apoptosis-stimulating protein of p53 (ASPP2) heterozygous mice are tumor-prone and have attenuated cellular damage-response thresholds" Proceedings of the National Academy of Sciences of the United States of America March 17 2009
  • "Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene" Cell Death and Differentiation April 2005
  • "Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cel and follicular center lymphoma" Leukemia and Lymphoma December 1 2002
  • "Attenuated expression of apoptosis stimulating protein of p53-2 (ASPP2) in human acute leukemia is associated with therapy failure" PLoS One November 27 2013
  • "New insights into the expanding complexity of the tumor suppressor ASPP2" Cell Cycle September 15 2009
  • "Safety and Outcomes Following Resection of Colorectal Liver Metastases in the Era of Current Perioperative Chemotherapy" Journal of Gastrointestinal Surgery December 2013
  • "Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites" Oncogene November 7 2002
  • "Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer" Molecular Cancer Research  2014
  • "hADA2a and hADA3" Cancer Biology and Therapy January 2008
  • "N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence" Proceedings of the National Academy of Sciences of the United States of America January 2 2013
  • "Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53" Molecular and Cellular Biology  2000
  • "E2F1 regulates the base excision repair gene XRCC1 and promotes DNA repair" Journal of Biological Chemistry May 30 2008
  • "Control of ASPP2/53BP2L protein levels by proteasomal degradation modulates p53 apoptotic function" Journal of Biological Chemistry October 14 2005
  • "Unusual topogenic sequence directs prion protein biogenesis" Science April 13 1990
  • "hADA2a and hADA3" Cancer Biology and Therapy January 2008
  • "Non-hydrophobic extracytoplasmic determinant of stop transfer in the prion protein" Nature February 15 1990
  • "Lapatinib and gemcitabine for metastatic pancreatic cancer" American Journal of Clinical Oncology February 2011
  • "Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer" Investigational New Drugs August 2009
  • "The p53 pathway promotes efficient mitochondrial DNA base excision repair in colorectal cancer cells" Journal of Cancer Research April 1 2006
  • "Inhibition of cell death by ribosomal protein L35a" Cancer Letters June 28 2002
  • "Deregulation of p53-interacting protein 53bp2 by chemotherapy drugs or proteasomal inhibition may modulate chemotherapy-induced cell death" Blood  2000
  • "Putting the pieces together" Journal of General Internal Medicine November 2013
  • "ΔN-ASPP2, a novel isoform of the ASPP2 tumor suppressor, promotes cellular survival" Biochemical and Biophysical Research Communications January 22 2017
  • "Colorectal Cancer Liver Metastasis" Cellular and Molecular Gastroenterology and Hepatology March 1 2017
  • "Chemoradiation for locally advanced unresectable pancreatic cancer - What now?" JAMA oncology June 1 2017
  • "Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer" Supportive Care in Cancer October 31 2017
  • "Colorectal Cancer-Associated Spontaneous Tumor Lysis Syndrome" Journal of Gastrointestinal Cancer April 25 2018
  • "A Phase II Study of Celecoxib with Irinotecan, 5-Fluorouracil, and Leucovorin in Patients with Previously Untreated Advanced or Metastatic Colorectal Cancer" American Journal of Clinical Oncology December 1 2018
  • "Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival" Science advances September 12 2018
  • "Updates in the systemic treatment of hepatocellular carcinoma" European Oncology and Haematology January 1 2018

Additional information

Edit profile